Povofortay Approved in Europe for Adults With Hidradenitis Suppurativa
Povofortay (povorcitinib) was approved in Europe as a once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa.
Povofortay (povorcitinib) was approved in Europe as a once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa.